Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian CancerSteffan T. Nawrocki, Jennifer S. Carew, Kevin R. Kelly et al.|Clinical Cancer Research|2013Cited by 117
Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidineValeria Visconte, Jennifer S. Carew, Mikkael A. Sekeres et al.|Leukemia|2015Cited by 26
Comprehensive Quantitative Proteomic Profiling of the Pharmacodynamic Changes Induced By MLN4924 in Acute Myeloid Leukemia Cells Reveals Rational Targets for Combination TherapyValeria Visconte, Jennifer S. Carew, Steffan T. Nawrocki et al.|Blood|2015Cited by 0
Supplementary Table 1 from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian CancerSteffan T. Nawrocki, Jennifer S. Carew, Kevin R. Kelly et al.|Unknown|2023Cited by 0
Supplementary Figure 2 from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian CancerSteffan T. Nawrocki, Jennifer S. Carew, Kevin R. Kelly et al.|Unknown|2023Cited by 0